LU91133I2 - Vesicare 10mg et 5 mg solifenacinum succinatum 10 mg et 5 mg. - Google Patents

Vesicare 10mg et 5 mg solifenacinum succinatum 10 mg et 5 mg.

Info

Publication number
LU91133I2
LU91133I2 LU91133C LU91133C LU91133I2 LU 91133 I2 LU91133 I2 LU 91133I2 LU 91133 C LU91133 C LU 91133C LU 91133 C LU91133 C LU 91133C LU 91133 I2 LU91133 I2 LU 91133I2
Authority
LU
Luxembourg
Prior art keywords
succinatum
solifenacinum
vesicare
diseases
salts
Prior art date
Application number
LU91133C
Other languages
English (en)
Other versions
LU91133I9 (en
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91133(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of LU91133I2 publication Critical patent/LU91133I2/fr
Publication of LU91133I9 publication Critical patent/LU91133I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Tea And Coffee (AREA)
  • External Artificial Organs (AREA)
LU91133C 1994-12-28 2005-01-28 Novel quinuclidine derivatives and medicinal composition thereof LU91133I9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (fr) 1994-12-28 1995-12-27 Nouveaux derives de quinuclidine et composition pharmaceutique les contenant

Publications (2)

Publication Number Publication Date
LU91133I2 true LU91133I2 (fr) 2005-03-29
LU91133I9 LU91133I9 (en) 2018-08-01

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91133C LU91133I9 (en) 1994-12-28 2005-01-28 Novel quinuclidine derivatives and medicinal composition thereof

Country Status (24)

Country Link
US (2) US6017927A (fr)
EP (1) EP0801067B1 (fr)
JP (1) JP3014457B2 (fr)
KR (1) KR100386487B1 (fr)
CN (1) CN1045601C (fr)
AT (1) ATE233761T1 (fr)
AU (1) AU695616B2 (fr)
CA (1) CA2208839C (fr)
DE (2) DE69529844T2 (fr)
DK (1) DK0801067T3 (fr)
ES (1) ES2193208T3 (fr)
FI (1) FI115631B (fr)
FR (1) FR04C0032I2 (fr)
HU (1) HU223778B1 (fr)
LU (1) LU91133I9 (fr)
MX (1) MX9704880A (fr)
NL (1) NL300141I1 (fr)
NO (4) NO2005012I1 (fr)
NZ (1) NZ298144A (fr)
PL (1) PL182344B1 (fr)
PT (1) PT801067E (fr)
RU (1) RU2143432C1 (fr)
TW (1) TW305842B (fr)
WO (1) WO1996020194A1 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
AU6610001A (en) 2000-06-27 2002-01-08 S A L V A T Lab Sa Carbamates derived from arylalkylamines
KR100869722B1 (ko) 2000-12-22 2008-11-21 알미랄 에이쥐 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용
HUP0303524A3 (en) 2000-12-28 2008-03-28 Almirall Ag Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same and their use
KR100874815B1 (ko) * 2001-07-10 2008-12-19 아스텔라스세이야쿠 가부시키가이샤 간질성 방광염 치료용 의약 조성물
JP4505227B2 (ja) 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
BR0311414A (pt) * 2002-06-07 2005-03-15 Yamanouchi Pharma Co Ltd Agente terapêutico para uma bexiga hiperativa
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
JP2006502985A (ja) 2002-07-08 2006-01-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体拮抗剤として有用な３，６−二置換アザビシクロ［３．１．０］ヘキサン誘導体
AU2002368152A1 (en) 2002-07-31 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
EP1545508A4 (fr) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd Derives d'azabicyclo ¬3.1.0 hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
CN1688544A (zh) 2002-08-23 2005-10-26 兰贝克赛实验室有限公司 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物
WO2004039801A1 (fr) * 2002-10-29 2004-05-13 Pharmacia & Upjohn Company Llc Derives de quinuclidinium en tant qu'agents antimuscariniques
WO2004052857A1 (fr) 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
EP1583741A1 (fr) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited Derives de 1-substitues-3-pyrrolidines comme antagonistes de recepteurs muscariniques
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PL1492519T3 (pl) * 2003-03-21 2007-04-30 Dynogen Pharmaceuticals Inc Sposób leczenia chorób dolnych dróg moczowych przez zastosowanie modulatorów podjednostki α2δ kanału wapniowego z modulatorami mięśni gładkich
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100406009C (zh) 2003-04-10 2008-07-30 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的取代的氮杂双环己烷衍生物
WO2004089899A1 (fr) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Derives d’azabicyclo hexanes 3,6-disubstitues en tant qu’antagonistes des recepteurs muscariniques
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
WO2004091597A2 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Procede pour traiter le syndrome du colon irritable
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
EP1714965A4 (fr) * 2004-02-09 2007-12-19 Astellas Pharma Inc Composition contenant du succinate de solifenacine
WO2005077364A1 (fr) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. Préparation transdermique de solifénacine et procédé d'amélioration de la perméabilité transdermique de celle-ci
WO2005087231A1 (fr) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Composition contenant de la solifenacine
JPWO2005087231A1 (ja) * 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
CN1934109B (zh) * 2004-03-25 2010-06-23 安斯泰来制药株式会社 用于固体制剂的索非那新或其盐的组合物
CA2561167C (fr) * 2004-03-25 2012-09-11 Astellas Pharma Inc. Composition pour la preparation pharmaceutique solide de solifenacine ou des sels de cette derniere
WO2006035280A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
MX2007007911A (es) * 2004-12-27 2007-08-20 Astellas Pharma Inc Composicion farmaceutica granular estable de solifenacina o su sal.
AU2005320672B2 (en) 2004-12-27 2011-01-06 Astellas Pharma Inc. Stable particulate pharmaceutical composition of solifenacin or salt thereof
US20090131469A1 (en) * 2005-02-25 2009-05-21 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
WO2007007281A2 (fr) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2007076116A2 (fr) * 2005-12-21 2007-07-05 Teva Pharmaceutical Industries Ltd. Procedes de preparation de solifenacine
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
WO2008011462A2 (fr) * 2006-07-19 2008-01-24 Dr. Reddy's Laboratories Ltd. Procédé de fabrication de solifénacine et de ses sels
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US20080114028A1 (en) * 2006-07-24 2008-05-15 Tamas Koltai Process for preparing polymorphic forms of solifenacin succinate
WO2008019103A2 (fr) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd Formes de solifénacine base et leur préparation
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CA2670365A1 (fr) * 2006-11-22 2008-05-29 Medichem S.A. Procede perfectionne pour la synthese de solifenacine
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
JP2010523539A (ja) * 2007-03-30 2010-07-15 メディチェム ソシエダ アノニマ ソリフェナシンの改良された合成法
EP2146693A2 (fr) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Compositions à base de solifénacine
US20090099365A1 (en) * 2007-07-13 2009-04-16 Nurit Perlman Processes for solifenacin preparation
CN101754760A (zh) * 2007-07-20 2010-06-23 安斯泰来制药株式会社 用以改善伴随着前列腺肥大的下尿路症状的药物组合物
EP2018850A1 (fr) * 2007-07-24 2009-01-28 Ratiopharm GmbH Composition pharmaceutique comportant de la solifénacine ou sel acceptable pharmaceutiquement
EP2216021B1 (fr) 2007-11-02 2012-10-17 Astellas Pharma Inc. Composition pharmaceutique pour traiter une vessie hyperactive
JP2011505416A (ja) * 2007-12-04 2011-02-24 カディラ ヘルスケア リミティド 化学的及びキラル的に純粋なソリフェナシン塩基及びその塩を調製する方法
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2271218B1 (fr) 2008-03-27 2017-05-24 Chase Pharmaceuticals Corporation Utilisation et composition permettant de traiter la démence
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
SI3067353T1 (en) 2008-07-29 2018-03-30 Krka, D.D., Novo Mesto Process for the preparation of solifenacin salts and their inclusion in pharmaceutical dosage forms
EP2181707A1 (fr) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Utilisation combinée d'un antagoniste de récepteur alpha-adrénergique et d'un agent anti-muscarinique
HUE029638T2 (en) 2009-02-04 2017-03-28 Astellas Pharma Inc Pharmaceutical preparation for oral administration
US8283470B2 (en) 2009-03-09 2012-10-09 Megafine Pharma(P) Ltd. Method for the preparation of solifenacin and intermediate thereof
JP4816828B2 (ja) 2009-03-30 2011-11-16 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (fr) * 2009-09-25 2011-04-28 Cadila Healthcare Limited Procédés de préparation de solifénacine ou d'un de ses sels
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
WO2011125763A1 (fr) 2010-03-31 2011-10-13 小野薬品工業株式会社 Agent préventif et/ou remède pour le syndrome d'enflure douloureuse des mains et des pieds
EP2563123B1 (fr) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Nouveaux agonistes du récepteur bêta 3 adrénergique
AU2011255951C1 (en) 2010-05-19 2015-02-19 Astellas Pharma Inc. Pharmaceutical composition containing solifenacin
WO2012001481A1 (fr) 2010-06-28 2012-01-05 Aurobindo Pharma Limited Nouveau procédé pour la préparation de succinate de solifénacine
US8765785B2 (en) 2010-07-05 2014-07-01 Crystal Pharma, S.A.U. Solifenacin salts
EP2638039A1 (fr) 2010-11-11 2013-09-18 Hexal AG Succinate de solifénacine cristallin
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
JP6068447B2 (ja) 2011-05-10 2017-01-25 セラヴィダ，インコーポレイテッド 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
JP2014520126A (ja) 2011-06-22 2014-08-21 イソケム ソリフェナシンおよびその塩の製造方法
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
JP2015521635A (ja) * 2012-07-02 2015-07-30 ファーマシェン エス．エー． ソリフェナシン又はその塩の調製方法
EA201590449A1 (ru) 2012-08-31 2015-06-30 Астеллас Фарма Инк. Перорально вводимая лекарственная композиция
AU2013312749B2 (en) 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
AR093832A1 (es) * 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
EP2778167A1 (fr) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique comprenant solifenacin ou l'un de ses sels pharmaceutiquement acceptable
US9751875B2 (en) * 2013-07-13 2017-09-05 Beijing Fswelcome Technology Development Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
EP3139924A4 (fr) 2014-05-06 2018-03-07 Anthony G. Visco Procédés de traitement ou de prévention du travail prématuré
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
TW201927783A (zh) * 2017-12-12 2019-07-16 美商阿爾庫達醫療公司 顆粒體蛋白前體調節劑及其使用方法
AR119149A1 (es) 2019-06-12 2021-11-24 Arkuda Therapeutics Derivados de isoquinolina como moduladores de la progranulina
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247266B1 (fr) * 1986-01-07 1993-03-10 Beecham Group Plc Dérivés d'indole ayant une chaîne latérale azabicyclique, procédé pour leur préparation, produits intermédiaires et compositions pharmaceutiques
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP1424021B1 (fr) * 2002-11-27 2006-09-13 Selmac S.r.l. Dispositif pour positionner et serrer des éléments préformés et machine équipée de ce dispositif

Also Published As

Publication number Publication date
JP3014457B2 (ja) 2000-02-28
EP0801067A1 (fr) 1997-10-15
JPH09508401A (ja) 1997-08-26
FI972775A (fi) 1997-08-22
FI115631B (fi) 2005-06-15
HUT77006A (hu) 1998-03-02
NO2005016I1 (no) 2005-08-29
HU223778B1 (hu) 2005-01-28
WO1996020194A1 (fr) 1996-07-04
NO318026B1 (no) 2005-01-24
EP0801067B1 (fr) 2003-03-05
NO2005012I1 (no) 2005-06-06
AU695616B2 (en) 1998-08-20
DK0801067T3 (da) 2003-06-30
AU4355396A (en) 1996-07-19
CN1045601C (zh) 1999-10-13
CA2208839A1 (fr) 1996-07-04
DE69529844D1 (de) 2003-04-10
KR987000303A (ko) 1998-03-30
NL300141I2 (nl) 2004-04-01
MX9704880A (es) 1997-10-31
CA2208839C (fr) 2006-01-31
ES2193208T3 (es) 2003-11-01
FR04C0032I1 (fr) 2005-02-11
PT801067E (pt) 2003-07-31
EP0801067A4 (fr) 1998-03-11
DE122004000048I1 (de) 2005-04-21
NZ298144A (en) 1998-04-27
DE122004000048I2 (de) 2006-02-02
NO2017055I2 (no) 2017-11-06
LU91133I9 (en) 2018-08-01
NO2005016I2 (no) 2008-02-11
PL182344B1 (pl) 2001-12-31
RU2143432C1 (ru) 1999-12-27
FR04C0032I2 (fr) 2005-10-21
FI972775A0 (fi) 1997-06-27
US6174896B1 (en) 2001-01-16
TW305842B (fr) 1997-05-21
DE69529844T2 (de) 2004-03-04
NL300141I1 (nl) 2004-04-01
US6017927A (en) 2000-01-25
ATE233761T1 (de) 2003-03-15
PL321019A1 (en) 1997-11-24
CN1171109A (zh) 1998-01-21
NO973027L (no) 1997-08-28
KR100386487B1 (ko) 2003-09-26
NO2017055I1 (no) 2017-11-06
NO973027D0 (no) 1997-06-27

Similar Documents

Publication Publication Date Title
LU91133I2 (fr) Vesicare 10mg et 5 mg solifenacinum succinatum 10 mg et 5 mg.
DE69111138T2 (de) Heterocyclische Verbindungen mit antiemetischer und Migräne unterdrückender Wirkung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen.
ATE109484T1 (de) Thienopyridin -derivative und diese enthaltende arzneimittel.
ZA916268B (en) Tricyclic compound or salts thereof,method for producing the same and antimicrobial agent containing the same
NO20014119L (no) Medikament inneholdende et sulfopyranosylacylglycerolderivat
ATE209204T1 (de) Piperidinderivate.
NO910904L (no) Fremgangsmaate for fremstilling av en substituert aminforbindelse.
DE69429185D1 (de) Imidazolidinon-derivate, deren säure-additionssalze und mittel gegen senile demenz
DE69300318D1 (de) Flavonderivate.
DK0580503T3 (da) Aminoalkylchromoner, fremgangsmåde til fremstilling heraf samt midler indeholdende disse
GR3022450T3 (en) Piperidine derivatives with antihistaminic and antileukohienic activity.
DK656889A (da) Azabicykliske derivater